Verastem(VSTM) - 2019 Q3 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For Q3 2019, total revenue was $9 million, with net product revenue of $4 million, a 33% increase from the previous quarter [11][43] - Year-to-date revenue from COPIKTRA reached $8.7 million, with expectations to meet the guidance of $12 million to $14 million for 2019 [12][50] - Net loss for Q3 2019 was $30.1 million, or $0.41 per share, compared to a net loss of $21.7 million, or $0.29 per share in Q3 2018 [48] Business Line Data and Key Metrics Changes - COPIKTRA's sales trajectory is positive, with a 30% increase in the number of prescribing physicians in Q3 compared to Q2 [12][14] - License and collaboration revenue for Q3 2019 was $5 million, down from $15 million in Q3 2018, which included a significant upfront payment from a prior agreement [44] Market Data and Key Metrics Changes - The company is focusing on expanding COPIKTRA's market presence in the U.S. and internationally, with a new partnership with Sanofi for development in 78 countries [22][23] - The company is also pursuing regulatory approval in Europe, with plans to submit a marketing authorization application by the end of 2019 [24] Company Strategy and Development Direction - The company announced a reduction of approximately $25 million in operating expenses for 2020, including a workforce reduction of about 40 positions [15][16] - The "6-2-5" corporate plan aims to achieve a positive revenue trajectory for COPIKTRA, cash-flow breakeven within two years, and broaden indications for the drug within five years [18][19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that COPIKTRA's sales ramp has been slower than expected but remains optimistic about achieving peak annual sales of $200 million to $300 million [14][15] - The company is committed to driving COPIKTRA adoption and expanding its footprint in other global markets and indications [20] Other Important Information - The company has made progress in clinical development, including ongoing studies for T-cell lymphoma and a Phase 2 study for patients with relapsed or refractory non-Hodgkin lymphoma [25][34] - The company presented multiple abstracts at medical meetings, supporting the ongoing development of COPIKTRA [31] Q&A Session Summary Question: How many of the eliminated positions were sales reps? - Approximately 14 of the 40 eliminated positions were within the sales organization, representing about 28% of the initial sales force [56] Question: What is the strategy for Europe and enrollment in PRIMO? - The company is filing for regulatory approval in Europe itself and is in discussions with potential partners. Enrollment in the PRIMO study is ahead of internal projections [60][62] Question: How does the company reconcile its guidance with current sales? - The company reiterated its guidance of $12 million to $14 million for 2019, acknowledging the uncertainty in seasonality affecting December sales [66][67] Question: What are the expectations for achieving peak sales? - The company believes that with improved infrastructure and focus on larger accounts, it can reach peak sales of $200 million to $300 million in the years following the launch [72][73] Question: What immediate cost savings or sales inflections are expected? - The company aims to achieve a trajectory that allows for cash flow breakeven within two years, with significant reductions in operating expenses already implemented [82][84]